Paul Wang joined Clinical Research Associates (CRA) and the Simons Foundation in 2016. He helps to oversee portions of SFARI’s clinical research portfolio, and CRA’s work with the experimental drug arbaclofen.
Wang is a graduate of Harvard College and Yale University School of Medicine. He trained in pediatrics at the University of Michigan and in developmental-behavioral pediatrics at Children’s Hospital of Philadelphia (CHOP). He also completed a research fellowship at the Salk Institute, where he studied the cognitive neuroscience of Williams and Down syndromes, pioneering the “genetics first” approach to research on neurodevelopmental conditions. Later, on the faculty of CHOP, Wang extended this approach to the 22q11.2 deletion syndrome. While at CHOP, he also provided medical care to hundreds of families affected by autism spectrum disorder (ASD) and related genetic conditions.
From 2002 to 2013, Wang worked in industry, at Pfizer and then at Seaside Therapeutics, providing leadership for clinical trials in adolescent schizophrenia and bipolar disorder, and for novel programs on fragile X syndrome and ASD. Paul also worked at Autism Speaks as Senior Vice President for medical research, helping to interpret research advances for a broad audience. Paul has served in leadership roles for the American Academy of Pediatrics, the American Board of Pediatrics, the Society for Developmental-Behavioral Pediatrics and the Williams Syndrome Association. He is a current member of the Interagency Autism Coordinating Committee of the U.S. Department of Health and Human Services.